Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy
Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) underway SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beij
Nov. 25, 2024